The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
MUSCAT, Oman, June 30, 2026 /PRNewswire/ -- Dar Global and FENDI Casa announce the launch of Azure Oceanfront Villas, a collection of ultra-luxury mansions...
LONDON, June 29, 2026 /PRNewswire/ -- On June 22, CATL and the Ellen MacArthur Foundation announced two new initiatives together with BMW, Renault, Volvo, Google, Xiaomi...
ZURICH, June 29, 2026 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced a...
LISHUI, China, June 29, 2026 /PRNewswire/ -- Farmmi, Inc. (NASDAQ: FAMI) (the "Company"), an agriculture products supplier in China and a logistics and supply...
GUANGZHOU, China, June 29, 2026 /PRNewswire/ -- XPENG (NYSE: XPEV, HKEX: 9868), a leading China-based high-tech company, shared insights at the CVPR 2026 Workshop...
